Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Telemedicine comparable to standard care in managing CF: Study

Telemedicine programs for managing cystic fibrosis (CF) were at least as effective as standard in-clinic care, according to a review study. Adhering to treatment regimens and patient satisfaction with telemedicine improved significantly across most studies examined, and most participants favored continuing with telemedicine. The review study, “…

New target may aid antibiotics in treating M. abscessus infection

A newly identified therapeutic target showed a potential to enhance the effectiveness of antibiotics against resistant Mycobacterium abscessus (Mabs) lung infection, a damaging complication in people with cystic fibrosis (CF), researchers report. Experiments using human airway organoids derived from CF patients also accurately reflected many features seen in their…

Children as young as 2 now may use digestion aid Relizorb

The U.S. Food and Drug Administration (FDA) will allow children with cystic fibrosis (CF) as young as age 2 to use Relizorb, an enzyme cartridge that connects with an enteral feeding tube to provide easier digestion of fats. “This additional RELiZORB clearance represents access for approximately 25% of…

CFTR modulators help enhance immune cell function: Study

CFTR modulator therapies can enhance the ability of certain immune cells to kill bacteria, independent of defects in the CFTR protein that cause cystic fibrosis (CF), according to a new study. Specifically, these modulators alter metabolic processes to activate anti-bacterial processes within both CF and non-CF immune cells known…

Campaign seeks to improve CF diagnosis after newborn screening

A Chicago children’s hospital is leading an awareness campaign to reduce the missed or delayed diagnosis of cystic fibrosis (CF) after newborn screening, especially in non-white infants. “Delays in diagnosis of cystic fibrosis increase the risk for severe illness,” Susanna McColley, MD, principal investigator and a pulmonologist at the…

Study: Underweight CF patients see biggest weight gains with Trikafta

People with cystic fibrosis (CF) who were underweight before treatment gained the most weight after six months on Trikafta (elexacaftor/tezacaftor/ivacaftor), according to a new study. Underweight participants, as assessed with the body mass index (BMI), also saw the biggest gains in treatment-related lung function. Patients who were overweight…